Journal of the European Academy of Dermatology and Venereology : JEADV
Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis.
Audrey Lasek, Nathalia Bellon, Stéphanie Mallet, Hélène Aubert, Carine Vera, Lamia Achour, Claire Thénié, Randy Prescilla, Claire Abasq-Thomas, Sébastien Barbarot
Published: 202510.1111/jdv.70268
Abstract
BACKGROUND: Dupilumab, a human monoclonal anti-interleukin-4/13 antibody, is approved for treating severe atopic dermatitis (AD) in children aged 6 months-5 years. It received approval for an Early Access Program (EAP) for children by the French Heal…
Preview only. Read the full abstract at the source